June 4, 2000--Vical Incorporated (Nasdaq:VICL - news) unveiled Vaxfectin, a novel agent that may enhance the efficiency of DNA vaccines, as part of a series of presentations by management and research scientists at the annual meeting of the American Society of Gene Therapy (ASGT).
Vaxfectin is Vical's novel cationic lipid formulation designed to enhance the efficiency of DNA vaccination. Vical's director of chemistry, Carl Wheeler, Ph.D., and research scientist Mary Wloch, Ph.D., described the formulation of Vaxfectin and presented data that documented the increased immune response. In preclinical testing, Vaxfectin was shown to boost the antibody immune response evoked by naked DNA vaccination as much as 10-fold without reducing the cell-mediated response.
Deirdre Y. Gillespie, M.D., Vical's Chief Operating Officer, said, ``We are pleased to share our recent developments in this exciting field with our peers in the American Society of Gene Therapy. We believe that our advances in research, product development, clinical trials, and manufacturing are helping to drive the industry toward a new era in medicine. We look forward to the day when gene-based treatments are broadly available in the health care market providing clinical benefit to patients.''
biz.yahoo.com |
